Cosmos Health to Launch Liv18™ U.S. Production in April 2026 With $5M Revenue Forecast
Cosmos Health finalized Phase 1 of Liv18™, completing product development, packaging and initial commercial setup ahead of schedule, and will begin U.S. production in April 2026 at a GMP-certified, FDA-registered facility. The company expects Liv18™ to deliver over $5 million in annual revenue with roughly 75% gross margins.
1. Phase 1 Execution Completed Ahead of Schedule
Cosmos Health has finalized Phase 1 execution for its Liv18™ liver health supplement, completing product formulation, packaging design and initial commercial infrastructure ahead of schedule to support U.S. market rollout.
2. U.S. Production to Begin April 2026
U.S. production is slated to begin in April 2026 at a GMP-certified, FDA-registered and UL-audited facility, enhancing supply chain efficiency, mitigating tariff risks and ensuring compliance with high regulatory standards.
3. Financial Projections and Commercial Strategy
The company projects that Liv18™ will generate over $5 million in annual revenue at approximately 75% gross margins, driven by a direct-to-consumer model, targeted digital marketing and confirmed early sales traction from existing Cosmos Health product lines.